Nonmelanocytic Skin and Soft Tissue Tumors

Nonmelanocytic skin and soft tissue tumors encompass a wide range of growths that originate from various components of the skin and its associated soft tissues, excluding those derived from melanocytes. Understanding these tumors is crucial for accurate diagnosis and effective treatment, particularly from a plastic surgeon's perspective. This comprehensive guide will break down their origins, diagnostic methods, classification, and treatment options, providing valuable insights for students and medical professionals.

Understanding Nonmelanocytic Skin and Soft Tissue Tumors

To grasp the nature of nonmelanocytic skin and soft tissue tumors, it's essential to first understand the development and components of skin. The skin is a complex organ derived from two primary embryonic layers: the epidermis from the superficial ectoderm, and the dermis from the mesenchyme. During early embryonic development (3–4 weeks), neural crest cells migrate into the epidermis, differentiating into melanocytes and Schwann cells, which are crucial for peripheral nerves in the skin.

As development progresses, cutaneous appendages like hair, sebaceous glands, eccrine, and apocrine sweat glands form from epidermal origins. Associated soft tissues such as fat, muscles, and blood vessels (all of mesenchymal lineage), and nerves (from neural crest cells) also contribute to the skin's structure. Therefore, skin and soft tissue tumors can be broadly classified by their origin:

• Epithelial origin
• Cutaneous appendage origin
• Neural crest origin (excluding melanocytic tumors)
• Mesenchymal origin

This article focuses on all typical skin and skin-associated soft-tissue tumors, specifically excluding malignant melanocytic tumors (malignant melanoma).

Diagnosing Nonmelanocytic Skin and Soft Tissue Tumors

The diagnostic process for nonmelanocytic skin and soft tissue tumors is thorough, combining visual and tactile examinations with advanced imaging and pathological analyses. Early detection and accurate differentiation between benign and malignant growths are paramount.

Initial Assessment: Inspection and Palpation

Diagnosis begins with a careful inspection and palpation of the lesion. Key information to record includes:

• Number of lesions: Solitary or multiple.
• Shape: Round, oval, polygonal, geographic, linear, annular.
• Size: Measured dimensions.
• Elevation status: Narrow-pedicled, wide-pedicled, dome-like, hemispherical, flat elevated, umbilicated.
• Surface status: Smooth, rough, papillary, granular, transudatory, xerophily, ulcerative, erosive, atrophic, lustrous, necrotic.
• Color: Normal, yellow, pale yellow, erythematous, blackish brown, black, blue, depigmented, pigmented, hyperemic, livid (color is particularly important for diagnosis).
• Hardness: Soft, elastic soft, elastic hard, hard, bone-like hard, fluctuating.
• Alignment: Localized, disseminated, centrifugal, systematized, singular, symmetric, asymmetric, bilateral.
• Site: Location on the body.
• Subjective symptoms: Pain, itch, contracture sensation, numbness, burning sensation, cold sensation.
• Time course: Acute, subacute, chronic, temporary, recurrent.

Rapid changes in a lesion's shape, size, elevation, or color are critical indicators that warrant considering a biopsy, as malignant tumors should always be suspected.

Specialized Diagnostic Techniques

Several specialized techniques aid in diagnosing nonmelanocytic skin and soft tissue tumors:

• Dermoscopy: This technique uses a binocular microscope to observe the skin surface, crucial for differentiating melanocytic from nonmelanocytic pigmented lesions. It's also vital for diagnosing seborrheic keratosis, basal cell carcinoma (BCC), and vascular lesions. A two-step diagnostic algorithm is often employed.

• Dermoscopic criteria for seborrheic keratosis: Multiple milia-like cysts, comedo-like openings, light-brown fingerprint-like structures, fissures/ridges.

• Dermoscopic criteria for basal cell carcinoma: Absence of pigment network, combined with arborizing vessels, leaf-like areas, large blue-gray ovoid nests, multiple blue-gray globules, spoke wheel areas, or ulceration.

• Dermoscopic criteria for vascular lesions: Red-blue lacunas, red-bluish to red-black homogeneous areas.

• Ultrasound and Doppler Imaging: High-frequency ultrasound (20–50 MHz) is used for skin lesions, while standard ultrasound (3–10 MHz) is for deeper lesions. Ultrasound helps determine tumor thickness, relationship with adjacent structures, and lymph node metastasis. Doppler imaging (Color Doppler Imaging or Power Doppler Imaging) is useful for differentiating benign from malignant tumors (90% of malignant tumors show high blood flow rates of 3–20 cm/s), assessing inflammation, and detecting lymph node metastases. M-mode and duplex scanning are used for hemangiomas or vascular malformations.

• X-ray, CT, MRI, Angiography, Scintigraphy, and PET:

• X-ray: Detects calcifying lesions (e.g., pilomatricoma) and necrosis-induced calcifications in malignant tumors. Also reveals bone deformation from tumor invasion.

• CT (Computed Tomography): Better than MRI for detecting metastatic lesions in bone, lymph nodes, and lungs. Contrast-enhanced CT and CT angiography help identify malignant tumors, vascular regions, and adjacent vascular structures.

• MRI (Magnetic Resonance Imaging): Superior for soft tissue detection. Malignant tumors generally show low-iso signal intensity on T2WI and low signal intensity on T1WI; benign tumors show high signal intensity on T2WI and low signal intensity on T1WI. Magnetic resonance angiography is excellent for hemangiomas and vascular malformations.

• Angiography: Invasive method, previously used for vascular lesions, but often requires general anesthesia for pediatric patients.

• Scintigraphy: Used for metastatic lesion screening (e.g., 67Ga, 201TiCl for tumors/inflammation; 99mTc-MDP, 99mTc-HMDP for bone). Suffers from low resolution (difficulty detecting lesions < 2 mm).

• PET (Positron Emission Tomography): Useful for detecting metastatic lesions. FDG-PET is used for cancer diagnosis, staging, and monitoring, especially for highly active tumors. However, it can also detect inflammatory lesions, requiring careful differentiation.

Pathologic Diagnosis: Biopsy Procedures

A definitive diagnosis requires pathological examination. Biopsies should always be performed with a clear purpose:

• Differential diagnosis of benign tumors.
• Analyzing stage and grade of malignant tumors to determine resection area.

Biopsies should only follow careful inspection, palpation, and imaging analyses. Surgeons select from various techniques based on purpose and lesion characteristics:

• Punch biopsy
• Incisional biopsy: Excises normal skin alongside early-stage lesions and characteristic areas (inflammatory, erosive, ulcerated).
• Excisional biopsy: Recommended for possible malignant tumors to prevent malignant cell dissemination. For low-grade malignant tumors (e.g., BCC), an excisional biopsy with several millimeters of normal skin margin might suffice as a radical resection. For high-grade tumors, it often leads to further treatment.
• Mapping biopsy

Sentinel node biopsy detects lymph node metastasis, indicating if cancer has spread to the first lymph node. It helps determine the need for full lymph node dissection, although its therapeutic value for survival benefit in negative nodes is debated due to the risk of lymphedema.

Classifying Malignant Tumors: The TNM System

The TNM clinical classification system (TNM) and pTNM pathologic classification system are used to describe the anatomical extent of malignant tumors and guide treatment. They apply only to malignant tumors.

• T (Tumor): Indicates tumor size and local invasion.
• TX: Primary tumor cannot be assessed.
• T0: No evidence of primary tumor.
• Tis: Carcinoma in situ.
• T1: Tumor ≤ 2 cm in greatest dimension.
• T2: Tumor > 2 cm but ≤ 5 cm.
• T3: Tumor > 5 cm.
• T4: Tumor invades deep extradermal structures (cartilage, skeletal muscle, or bone).
• N (Nodes): Indicates regional lymph node involvement.
• NX: Regional lymph nodes cannot be assessed.
• N0: No regional lymph node metastasis.
• N1: Regional lymph node metastasis.
• M (Metastasis): Indicates distant metastasis.
• MX: Distant metastasis cannot be assessed.
• M0: No distant metastasis.
• M1: Distant metastasis present.

Clinical Staging

For tabulation and analysis, TNM categories are condensed into stages:

• Stage 0: Carcinoma in situ (Tis N0 M0).
• Stage I: Localized to organ of origin (T1 N0 M0).
• Stage II: Localized, larger tumor (T2 N0 M0; Stage I tumors with high-risk features may be Stage II by AJCC).
• Stage III: Extensive local spread, particularly to regional lymph nodes (T3 N0 M0 or T1,2,3 N1 M0).
• Stage IV: Distant metastasis (T1,2,3 N2,3 M0 or T4 AnyN M0 or AnyT AnyN M1).

Pathological staging (pTNM) is used after intraoperative and surgical pathologic data are available. For pN assessment, at least six lymph nodes are usually needed for histological examination.

Treatment Approaches for Skin and Soft Tissue Tumors

Treatment for nonmelanocytic skin and soft tissue tumors is multi-faceted, ranging from surgical removal to adjuvant therapies, and varies based on tumor type, stage, and location.

Surgical Interventions

• Wide Excision: This involves removing the tumor with a margin of healthy tissue. Horizontal and vertical margins depend on the tumor type.

• Horizontal margins:

• 3–5 mm for Bowen’s disease, solar keratosis, basal cell carcinoma.

• 10–30 mm for Squamous cell carcinoma, malignant appendage-origin tumors, extramammary Paget’s disease, Merkel cell carcinoma, malignant mesenchymal-origin tumors.

• 50 mm for malignant soft-tissue tumors.

• Vertical margins: Vary from fat layer (for dermal tumors) to deeper structures like cartilage or bone (for invading tumors). At least one barrier structure layer (e.g., deep fascia) should be excised.

• Mohs Micrographic Surgery: Crucial for complete margin control, especially for skin cancers and soft-tissue sarcomas, allowing histological analysis during surgery to confirm tumor-free margins.

• Lymph Node Dissection:

• Axillary Lymph Node Dissection: Less common due to sentinel lymph node biopsy, but indicated for metastatic squamous cell carcinoma (SCC).

• Inguinal Lymph Node Dissection: Also less frequent with sentinel node use, but indicated for metastatic SCC and extramammary Paget’s disease (EMPD).

• Reconstructive Surgery: Addresses tissue defects after tumor removal. Direct wound closure is ideal for smaller defects. Advanced techniques include skin grafting, local flaps, and other methods. The